We apply innovative engineering approaches that leverage the natural virology of Papillomaviruses, creating platform delivery medicines that possess unique mechanisms of action.
Papillomavirus Virus-like Particles and their derivatives can act as broad platforms which can be utilized and applied in many ways. They have been demonstrated to be safe in humans, are highly immunogenic and recently, found to be tumor-specific due to the virus’s natural need to infect wounded sites, in which solid tumors also emulate.
Our team at PathoVax, collaborators, and advisors have published several publications pioneering the use of papillomavirus particles for numerous broad therapeutic applications. The publications below represent a sample of existing innovative and foundational work